ArticleMolecular cancer2022
Identification of tumor tissue-derived DNA methylation biomarkers for the detection and therapy response evaluation of metastatic castration resistant prostate cancer in liquid biopsies.
Abstract readLetter
In one paragraph
Article in Molecular cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Evaluation of a Methylated Circulating Tumour DNA Panel for Detection and Disease Stratification in Prostate Cancer.International journal of molecular sciences · 2026Article
- Comprehensive molecular characterization of cfDNA as predictive and monitoring biomarkers in advanced gastric cancer receiving immunotherapy.Journal for immunotherapy of cancer · 2026Article
- Clinical impact of the methylation status of SMAD4 and AKR1B1 genes in a liquid biopsy sample as a prognostic marker for breast cancer.Scientific reports · 2026Article
- The role of multimodality imaging in selection, response assessment, and follow-up of patients receivingInsights into imaging · 2026Article
- Methylation-specific, universal, and highly sensitive identification of ctDNA in prostate cancer by multiplex droplet digital PCR.PloS one · 2026Article
- Plasma cell-free DNA methylation-based prognosis in metastatic castrate-resistant prostate cancer.NPJ precision oncology · 2025Article
- Advancements in DNA methylation technologies and their application in cancer diagnosis.Epigenetics · 2025Review
- Bladder cancer diagnostic and prognostic models from DNA methylation by multi algorithm machine learning.NPJ precision oncology · 2025Article
- The Years 2015-2025 as a Prospective Decade for the Identification of Specific Methylation Biomarkers of Prostate Cancer.Biomolecules · 2025Review
- Multiple highly methylated CpG sites as potential epigenetic markers for the diagnosis of prostate cancer.Clinical epigenetics · 2025Article
- A DNA alteration and methylation co-detection method for clinical purpose.EMBO molecular medicine · 2025Article
- Does circulating DNA tumor fraction add value to prostate-specific antigen in metastatic castration-resistant prostate cancer?Translational cancer research · 2025Article
- Article
- Imaging and outcome correlates of ctDNA methylation markers in prostate cancer: a comparative, cross-sectional [⁶⁸Ga]Ga-PSMA-11 PET/CT study.Clinical epigenetics · 2025Article
- Epigenetic modifications in follicular cell-derived thyroid cancer: new dimensions in pathogenesis and treatment.Frontiers in oncology · 2025Review
- Development and validation of the utLIFE-PC algorithm for noninvasive detection of prostate cancer in urine: A prospective, observational study.Cell reports. Medicine · 2024Observational
- A review on trends in development and translation of omics signatures in cancer.Computational and structural biotechnology journal · 2024Review
- Review
- Castration-resistant prostate cancer monitoring by cell-free circulating biomarkers.Frontiers in oncology · 2024Review
- Circulating Tumor DNA Biomarkers for Response Assessment in Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Thomas DillingerLudwig Boltzmann Institute Applied Diagnostics, Vienna, Austria.
Raheleh Sheibani-TezerjiLudwig Boltzmann Institute Applied Diagnostics, Vienna, Austria.ORCID 0000-0002-1025-646X
Walter PulvererHealth & Environment Department, Molecular Diagnostics, AIT-Austrian Institute of Technology GmbH, Vienna, Austria.
Ines StelzerLudwig Boltzmann Institute Applied Diagnostics, Vienna, Austria.
Melanie R HasslerDepartment of Pathology, Medical University of Vienna, Vienna, Austria.
Janine ScheibelreiterDepartment of Pathology, Medical University of Vienna, Vienna, Austria.
Carlos Uziel Pérez MallaLudwig Boltzmann Institute Applied Diagnostics, Vienna, Austria.
Madeleine KurollLudwig Boltzmann Institute Applied Diagnostics, Vienna, Austria.
Sandra DomazetLudwig Boltzmann Institute Applied Diagnostics, Vienna, Austria.
Elisa RedlDepartment of Pathology, Medical University of Vienna, Vienna, Austria.
Sarah ElyLudwig Boltzmann Institute Applied Diagnostics, Vienna, Austria.
Stefanie BrezinaInstitute of Cancer Research, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Andreas TiefenbacherLudwig Boltzmann Institute Applied Diagnostics, Vienna, Austria.
Katharina RebhanDepartment of Urology, Medical University Vienna, Vienna, Austria.
Nicolai HübnerDepartment of Urology, Medical University Vienna, Vienna, Austria.
Bernhard GrubmüllerDepartment of Urology, Medical University Vienna, Vienna, Austria.ORCID 0000-0002-8746-1488
Markus MitterhauserLudwig Boltzmann Institute Applied Diagnostics, Vienna, Austria.ORCID 0000-0003-3173-5272
Marcus HackerDivision of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Vienna, Austria.ORCID 0000-0002-4222-4083
Andreas WeinhaeuselHealth & Environment Department, Molecular Diagnostics, AIT-Austrian Institute of Technology GmbH, Vienna, Austria.ORCID 0000-0002-9318-1204
Judit SimonLudwig Boltzmann Institute Applied Diagnostics, Vienna, Austria.ORCID 0000-0001-9279-8627
Markus ZeitlingerLudwig Boltzmann Institute Applied Diagnostics, Vienna, Austria.ORCID 0000-0002-1873-3953
Andrea GsurInstitute of Cancer Research, Department of Medicine I, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-9795-1528
Gero KramerDepartment of Urology, Medical University Vienna, Vienna, Austria.
Shahrokh F ShariatDepartment of Urology, Medical University Vienna, Vienna, Austria.ORCID 0000-0002-6627-6179
Lukas KennerDepartment of Pathology, Medical University of Vienna, Vienna, Austria.ORCID 0000-0003-2184-1338
Gerda EggerLudwig Boltzmann Institute Applied Diagnostics, Vienna, Austria. gerda.egger@meduniwien.ac.at.ORCID 0000-0003-2489-155X
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Biomarkers, TumorDNA MethylationLiquid BiopsyComputational BiologyDisease ManagementDisease SusceptibilityEpigenesis, GeneticEpigenomicsGene Expression ProfilingHumansMalePrognosisProstatic Neoplasms, Castration-ResistantTreatment OutcomeBiomarkers, Tumor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.